Based on the Neighbourly Pharmacy Inc stock forecast from 9 analysts, the average analyst target price for Neighbourly Pharmacy Inc is CAD 23.67 over the next 12 months. Neighbourly Pharmacy Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Neighbourly Pharmacy Inc is Bullish , which is based on 8 positive signals and 3 negative signals. At the last closing, Neighbourly Pharmacy Inc’s stock price was CAD 17.75. Neighbourly Pharmacy Inc’s stock price has changed by -4.26% over the past week, -2.47% over the past month and -38.58% over the last year.
No recent analyst target price found for Neighbourly Pharmacy Inc
No recent average analyst rating found for Neighbourly Pharmacy Inc
Company Overview Neighbourly Pharmacy Inc
Neighbourly Pharmacy Inc. owns and operates a chain of retail pharmacies in Canada. The company sells prescription medication, confections and food, over the counter drugs, and health and beauty aids. It operates pharmacies under the various banners, such as IDA/Guardian, Pharmachoice, Pharmasave, Remedy's RX, and Drug Trading. The company was incorporated in 2015 and is headquartered in Toronto, Canada. Read Less
Neighbourly Pharmacy Inc. owns and operates a chain of retail pharmacies in Canada. The company sells prescription medication, confections and food, over the counter drugs, and health and beauty aids. It operates pharmacies under the various banners, such as IDA/Guardian, Pharmac...Read More
Frequently Asked Questions About Neighbourly Pharmacy Inc (NBLY:CA) Stock
Based on ratings from 9 analysts Neighbourly Pharmacy Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 10 buy, 1 sell and 9 hold ratings.
NBLY:CA stock's dividend yield is 1.04%.
Our analysis grades NBLY:CA stock's dividend yield at A+. This means that NBLY:CA stock's dividend yield is above 100% of the stocks in the Pharmaceutical Retailers sector in the TSX exchange.
Based on this NBLY:CA may be a good dividend stock for its sector.
Based on targets from 9 analysts, the average taret price for NBLY:CA is CAD 23.67 over the next 12 months. The maximum analyst target price is CAD 34 while the minimum anlayst target price is CAD 8.5.
NBLY:CA stock's Price/Earning ratio is 69.35.
Our analysis grades NBLY:CA stock's Price / Earning ratio at A+. This means that NBLY:CA stock's Price/Earning ratio is above 0% of the stocks in the Pharmaceutical Retailers sector in the TSX exchange.
Based on this NBLY:CA may be undervalued for its sector.
The last closing price of NBLY:CA's stock was CAD 17.75.
The most recent market capitalization for NBLY:CA is CAD 0.77B.
Based on targets from 9 analysts, the average taret price for NBLY:CA is projected at CAD 23.67 over the next 12 months.
This means that NBLY:CA's stock price may go up by +33.33% over the next 12 months.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NBLY:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
